Health Care & Life Sciences » Pharmaceuticals | Endo International PLC

Endo International PLC | Cash Flow

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
632
718
1,495
3,347
2,035
1,031
Depreciation, Depletion & Amortization
256
332
621
983
984
724
Other Funds
57
3
23
64
87
967
Funds from Operations
239
486
363
1,054
106
664
Changes in Working Capital
60
824
301
529
448
397
Net Operating Cash Flow
299
338
62
524
554
267
Capital Expenditures
108
85
126
158
126
Sale of Fixed Assets & Businesses
10
55
1,589
11
223
Purchase/Sale of Investments
-
-
87
1
-
Net Investing Cash Flow
113
991
6,225
189
105
Issuance/Reduction of Debt, Net
534
543
4,104
337
80
Net Financing Cash Flow
580
303
6,095
394
167
Net Change in Cash
767
355
75
59
494
Free Cash Flow
202
257
20
386
428
Deferred Taxes & Investment Tax Credit
156
275
447
745
156
6
Net Assets from Acquisitions
4
1,087
7,690
30
-
Other Sources
-
1
74
-
7
Change in Capital Stock
102
243
2,014
7
-
Exchange Rate Effect
-
2
4
7
3
Other Uses
12
35
1
12
-

About Endo International

View Profile
Address
Minerva House
Dublin Dublin 4
Ireland
Employees -
Website http://www.endo.com
Updated 07/08/2019
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The company operates through the following segments: U.